Atopic dermatitis in children: What to do when nothing works

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 2, 2010, Pages 303-308

  Kienast, A K ^a   Hoeger, P H ^b  

^a Berufsgenossenschaftliche Unfallkrankenhaus Hamburg   (Germany)

^b Catholic Children's Hospital Wilhelmstift   (Germany)

Author keywords

Compliance; Dermatitis, atopic; Patient education; Treatment failure

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE ACETATE; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNICARBATE; PREDNISOLONE;

ATOPIC DERMATITIS; CUSHING SYNDROME; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDUCATION PROGRAM; GROWTH RETARDATION; HEALTH EDUCATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; OSTEOPOROSIS; PHOTOTHERAPY; SHORT SURVEY; SKIN ATROPHY; TREATMENT DURATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 77954506424     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (51)

1. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000;118:40-3.
2. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006;155:145-51.
3. Williams JR, Burr ML, Williams HC. Factors influencing atopic dermatitis-a questionnaire survey of schoolchildren's perceptions. Br J Dermatol 2004;150;1154-61.
4. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol 2007;6:416-23.
5. Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003;149:582-9.
6. Chamlin SL, Kao J, Frieden D, Sheu MY, Fowler AJ, Fluhr JW et al. Cermaide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208.
7. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A et al.. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis: J Eur Acad Dermatol Venereol 2009;31 [Epub ahead of print].
8. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/ American Academy of Allergy, Asthma and Immunology/ PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-69.
9. Krejci- Manwaring J, McCarty MA, Camacho F, Carroll CL, Johnson K, Manuel J et al. Adherence with topical treatment is poor compared with adherence with oral agents: implications for effective clinical use of topical agents. J Am Acad Dermatol 2006;54:235-6.
10. Krejci- Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007;56:211-6.
11. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: review of the literature and recommendations for research. Clin Child Fam Psychol Rev 2003;6:17-30. (Pubitemid 38979780)
12. Green C, Coloquitt JL, Kirby J, Davidson P. Toical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs more frequent use. Br J Dermatol 2005;152:130-41. (Pubitemid 40193845)
13. Anstey A. Management of atopic dermatitis: nonadherence tp topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema. Br J Dermatol 2009;161:219-20.
14. Gupta G, Mallefet P, Kress DW, Sergeant A. Adherence to topical dermatological therapy: lessons from oral drug treatment. Br J Dermatol 2009;161:221-7.
15. Anderson PC, Dinulos JG. Atopic dermatitis and alternative management strategies. Cun Opin Pediatr 2009;21:131-8.
16. Witt CM, Brinkhaus B, Pach D, Reinhold T, Wruck K, Roll S et al. Homeopathic versus conventional therapy for atopic eczema in children: medical and economic results. Dermatology 2009;219:329-40.
17. Feldmann SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007;57:81-3. (Pubitemid 46908856)
18. van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res 2007;7:55-67.
19. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540-50. (Pubitemid 46513223)
20. Chavigny JM. The role of therapeutic education in the treatment of atopic dermatitis in children. Ann Dermatol Venereol 2005;132 No 1:1S116-20.
21. Staab D, Diepgen TL, Fartasch M, Kupfer J, Lob-Corzilius T, Ring J et al. Age related, structured educational programmes fort he management of atopic dermatitis in children and adolescents: multicentre, randomized controlled trial. BMJ 2006;332:933-8.
22. Grüber C, Illi S, Lau S, Nickel R, Forster J, Kamin W et al. Transient suppression of atopy in early childhood is associated with high vaccination coverage. Pediatrics 2003;111:e282-8.
23. Kreth HW, Hoeger PH, Memebers of the VZV-AD- study group. Safety, reatogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. Eur J Pediatr 2006;165:677-83.
24. Kunz B, Ring J. Clinical features and diagnostic criteria of atopic dermatitis. In: Harper J, Oranje A, Prose N, editors. Textbook of pediatric dermatology. Oxfors: Blackwell Publishing. 2nd edition; 2006.
25. Clark RA, Adinoff AD. The relationship between positive aeroallergen patch test reactions and aeroallergen exacerbation of atopic dermatitis. Clin Immunol Immunopathol 1989;53:132-40.
26. Young E. Seasonal factors in atopic dermatitis and their relationship to allergy. Acta Dermatol Venereol 1980;92:111-2.
27. Goodyear HM, Spowart K, Harper JI. 'Wet-wrap' dressings for the treatment of atopic eczema in children. Br J Dermatol 1991; 125:604.
28. Oranje AP, Devillers AC, Kunz B, Jones SL, DeRaeve L, Van Gysel D et al. Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. J Eur Acad Dermatol Venereol 2006;20:1277-86.
29. Tabata N, O'Goshi K, Zhen YX, Kligman AM, Tagami H. Biophysical assessment of persistent effects of moisturizers after their daily apllications: Evaluation of corneotherapy. Dermatology 2000;200:308-13. (Pubitemid 30451578)
30. Lodén M. The skin barrier and use of moisturizers in atopic dermatitis. Clin in Dermatol 2003;21:145-57.
31. Lodén M, Andersson AC, Anderson C, Bergbrant IM, Frödin T, Ohman H et al. A double- blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients. Acta Derm Venereol 2002;82:45-7.
32. Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC et al. Topical skin therapy with glucocorticoids - therapeutic index. J Dtsch Dermatol Ges 2004;2:629-34.
33. Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002;147:528-37. (Pubitemid 35015290)
34. Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: a randomized, double blind, parallel group study. BMJ 2003;326:1367-72.
35. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis- an emerging concept. Allergy 2009;64:276-8.
36. Wellenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E et al. A novel approach to disease control with 0.1% tacrolimus ointment in adults with atopic dermatitis: results of a randomized, mulitcentre, comparative study. Allergy 2008;63:742-50.
37. Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008;159:1348-56.
38. Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized , dose- response study. Allergy 2006;61:202-5.
39. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen -activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) pathway. J Allergy Clin Immunol 2004;114:1059-69. (Pubitemid 39469145)
40. Leung DYM, Hanifin JM, Pariser DM, Barber KA, Langley RG, Schlievert PM et al. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids; a randomized muti-centre, vehicle-controlled trial. Br J Dermatol 2009;161:435-43.
41. Schmitt J, Schäkel K, Fölster- Holst R, Bauer A, Oertel R, Augustin M et al. Prednisolone vs Ciclosporin for severe adult eczema. An investigator double- blind placebo- controlled multicentre trial. Br J Dermatol 2010;162:661-8.
42. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S et al. Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996;34:1016-21.
43. Bunikowski R, Staab D, Kussedbi F. Low- dose cyclosporin. A microemulsion in children with severe atopic dermatitis: clinical and immunological effects. Pedaitr Allergy Immunol 2001;12:216-23.
44. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema- a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007;21:606-19.
45. Sowden JM, Berth-Jones J, Ross JS, Allen BR, Berth-Jones J, Camp RD et al. Double-blind, controlled, crossover study of cyclosporine in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
46. Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs 2009;69:297-306.
47. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000;142:52-8.
48. Lau K, Hoeger PH. Antiinflammatorische Therapie des atopischen Ekzems im Kindesalter. Allergologie 2010, 33. in press.
49. Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007;157:127-32.
50. Weatherhead SC, Wahie S, Reynolds NJ, Meggitt SJ. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol 2007;156:346-51.
51. Murphy L-A, Atherton D. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression. Br J Dermatol 2002;147:308-15.